30 related articles for article (PubMed ID: 11853286)
1. Influence of sex hormones status and type of training on regional bone mineral density in exercising females.
Guisado-Cuadrado I; Alfaro-Magallanes VM; Romero-Parra N; Rael B; Guadalupe-Grau A; Peinado AB
Eur J Sport Sci; 2023 Nov; 23(11):2139-2147. PubMed ID: 37161678
[TBL] [Abstract][Full Text] [Related]
2. Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India.
Shah D; Patil M;
J Hum Reprod Sci; 2018; 11(2):96-118. PubMed ID: 30158805
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive use in young women is associated with lower bone mineral density than that of controls.
Almstedt Shoepe H; Snow CM
Osteoporos Int; 2005 Dec; 16(12):1538-44. PubMed ID: 15902418
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and history of oral contraceptive use.
Fortney JA; Feldblum PJ; Talmage RV; Zhang J; Godwin SE
J Reprod Med; 1994 Feb; 39(2):105-9. PubMed ID: 8169923
[TBL] [Abstract][Full Text] [Related]
5. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
7. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
8. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
9. Difference in bone acquisition among hormonally treated postmenopausal women with normal and low bone mass.
Taechakraichana N; Jaisamrarn U; Panyakhamlerd K; Chaikittisilpa S; Limpaphayom K
J Med Assoc Thai; 2001 Oct; 84 Suppl 2():S586-92. PubMed ID: 11853286
[TBL] [Abstract][Full Text] [Related]
10. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
11. [Low-dose oral contraception and bone density].
Karck U; Breckwoldt M
Ther Umsch; 2001 Sep; 58(9):547-51. PubMed ID: 11594153
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive use in osteoporosis.
Khoyi AA; Middleton RK
Ann Pharmacother; 1992 Sep; 26(9):1094-5. PubMed ID: 1421674
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
